Valuation: Abivax

Market Cap 9.52B 11.12B 8.91B 8.16B 15.31B 1,064B 15.51B 105B 41.06B 534B 41.75B 40.84B 1,768B P/E 2026 *
-28.7x
P/E 2027 * -33.8x
Enterprise Value 8.42B 9.83B 7.88B 7.21B 13.54B 941B 13.72B 93.1B 36.31B 473B 36.92B 36.11B 1,563B EV / Sales 2026 *
112x
EV / Sales 2027 * 103x
Free-Float
92.81%
Yield 2026 *
-
Yield 2027 * -
1 day+1.60%
1 week-0.88%
Current month-4.23%
1 month-11.79%
3 months-3.87%
6 months-9.43%
Current year-15.45%
1 week 99.55
Extreme 99.55
105.9
1 month 99.55
Extreme 99.55
117.2
Current year 60.45
Extreme 60.45
139
1 year 60.45
Extreme 60.45
139
3 years 4.51
Extreme 4.51
139
5 years 4.51
Extreme 4.51
139
10 years 3.87
Extreme 3.87
139
Manager TitleAgeSince
Chief Executive Officer 68 2023-05-04
Director of Finance/CFO 63 2017-01-01
Chief Tech/Sci/R&D Officer - 2023-09-30
Director TitleAgeSince
Chairman 66 2022-08-15
Chairman 68 2023-05-04
Director/Board Member 60 2023-07-10
Date Insider Type Main position Quantity % Market Cap.
7/15/26 Sell

Chairman

-3,375 0.0042%
7/11/26 Fiscal year

Chief Executive Officer

17,728 0.0222%
7/11/26 Fiscal year

Chairman

12,500 0.0157%
Change 5-day change 1-year change 3-year change Capi.($)
+1.60%-0.88%+53.08%+496.02% 11.12B
+1.09%+5.26%+4.52%+26.24% 51.61B
-1.07%+2.82%+465.96%+586.75% 44.89B
+1.47%+9.79%+35.92%+21.40% 42.77B
+1.44%+7.77%+19.38%+92.75% 42.58B
-0.93%-4.33%+16.18%+53.76% 31.82B
+1.32%+7.30%+33.89%+150.10% 17.33B
-0.60%+1.93% - - 16.63B
+0.03%+3.41%+6.55%+32.10% 14.76B
+1.28%+5.41%+82.40%+47.43% 14.09B
Average +0.56%+3.90%+79.76%+167.40% 28.76B
Weighted average by Cap. +0.53%+4.50%+97.67%+160.65%

Financials

2026 *2027 *
Net sales 74.92M 87.47M 70.1M 64.17M 120M 8.37B 122M 828M 323M 4.2B 328M 321M 13.9B 82.73M 96.58M 77.41M 70.86M 133M 9.24B 135M 915M 357M 4.64B 363M 355M 15.35B
Net income -265M -310M -248M -227M -426M -29.61B -432M -2.93B -1.14B -14.88B -1.16B -1.14B -49.21B -231M -269M -216M -198M -371M -25.77B -376M -2.55B -995M -12.95B -1.01B -989M -42.82B
Net Debt -1.1B -1.29B -1.03B -944M -1.77B -123B -1.8B -12.19B -4.75B -61.86B -4.83B -4.73B -205B -993M -1.16B -929M -850M -1.6B -111B -1.62B -10.97B -4.28B -55.69B -4.35B -4.26B -184B
Logo Abivax
Abivax is a clinical-stage biotechnology company focused on the development of therapeutics that exploit the body's natural regulatory mechanisms to stabilize the immune response in patients suffering from chronic inflammatory diseases. Based in France and the United States, Abivax's lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderate to severe active ulcerative colitis.
Employees
80
Date Price Change Volume
26-08-21 €101.80 +1.60% 86,068
26-08-20 €100.20 -3.00% 101,763
26-08-19 €103.30 +0.39% 88,269
26-08-18 €102.90 -2.83% 61,836
26-08-17 €105.90 +3.12% 121,638
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
101.80EUR
Average target price
138.97EUR
Spread / Average Target
+36.51%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ABVX Stock